KeyCorp Forecasts Strong Price Appreciation for Certara (NASDAQ:CERT) Stock

Certara (NASDAQ:CERT - Free Report) had its price target increased by KeyCorp from $15.00 to $18.00 in a research report report published on Wednesday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Several other equities analysts have also issued reports on CERT. William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays dropped their price objective on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Stephens reissued an "overweight" rating and issued a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Robert W. Baird increased their price objective on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Finally, TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $15.17.

Certara Trading Up 0.1 %

Certara stock traded up $0.01 during trading on Wednesday, hitting $14.16. The company had a trading volume of 552,141 shares, compared to its average volume of 1,186,274. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company's 50 day simple moving average is $11.62 and its 200-day simple moving average is $11.47. Certara has a 1-year low of $8.64 and a 1-year high of $17.94. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -70.80, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CERT. Janney Montgomery Scott LLC acquired a new position in Certara in the first quarter valued at approximately $120,000. SG Americas Securities LLC lifted its position in Certara by 350.1% in the first quarter. SG Americas Securities LLC now owns 69,727 shares of the company's stock valued at $690,000 after acquiring an additional 54,235 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Certara by 16.2% in the first quarter. Harbor Capital Advisors Inc. now owns 20,294 shares of the company's stock valued at $201,000 after acquiring an additional 2,834 shares in the last quarter. Portside Wealth Group LLC acquired a new position in Certara in the first quarter valued at $104,000. Finally, Kopion Asset Management LLC increased its position in shares of Certara by 8.0% during the first quarter. Kopion Asset Management LLC now owns 600,159 shares of the company's stock worth $5,942,000 after purchasing an additional 44,516 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.